登录新浪财经APP 搜索【信披】查看更多考评等级 智通财经1月8日讯（记者 武超）因自愿披露的公司与深圳脑机星链科技有限公司（简称"脑机星链"） 签署战略合作框架协议的相关公告信息不准确、不完整，亚辉龙（688575.SH）及公司董秘王鸣阳被上 海证券交易所予以监管警示。 上交所在其昨日晚间发布的《关于对深圳市亚辉龙生物科技股份有限公司及有关责任人予以监管警示的 决定》中指出，当前"脑机接口"为市场热点概念，为投资者高度关注，公司披露涉及热点相关信息尤其 应当审慎，确保相关信息披露真实、准确、完整，避免对投资者产生误导。 对于可能的股权投资，公司表示，短期内不排除有股权投资、合资等合作安排，但预计投资金额较小， 对公司不会有重大影响。公司根据脑机星链的具体融资计划及估值综合考虑对脑机星链的投资规模将不 超过人民币1500万元。 同时，公司表示，拟投资脑机星链金额"占公司货币资金的比例较低，不会对公司正常经营造成重大影 响"。公告显示，受行业政策影响，2025年1-9月，公司实现营业收入12.87亿元，同比下降7.69%；归属 于上市公司股东的净利润6042.09万元，同比下降72.36%。 上交所要求，亚辉龙 ...

Core Viewpoint - The news highlights the significant advancements and support for specialized and innovative small and medium-sized enterprises (SMEs) in Hai'an, Jiangsu Province, showcasing the successful implementation of policies and initiatives that foster growth and technological innovation in the region [1][2][3][4][5] Group 1: Technological Advancements - Jiangsu Beichen Hubang Electric Co., Ltd. has developed the world's first underground transformer product capable of being buried 7 meters deep, which is now entering the technical review stage [1] - The company has implemented a 5G smart workshop where industrial robots efficiently complete core stacking, allowing for full-process control with a simple mouse click [1] Group 2: Government Support and Policy Framework - Hai'an has established a four-dimensional work system of "service + policy + cultivation + platform" to optimize the industrial ecosystem and support enterprise growth [1] - The city has recognized 40 national-level specialized and innovative "little giant" enterprises and 8 national-level manufacturing single champion demonstration enterprises, leading in Nantong [1] - A series of special policies have been introduced to create a supportive system that integrates finance, technology, and talent, ensuring comprehensive service for enterprises [3] Group 3: Enterprise Growth and Development - Jiangsu Minglida Technology Co., Ltd. has received government support during its initial phase and has been recognized as a national-level specialized and innovative "little giant" after 8 years of operation [2] - Hai'an has implemented a tiered cultivation system for enterprises, focusing on innovation and the development of high-growth potential companies [2] - The city aims to achieve full coverage of visits to specialized and innovative "little giant" enterprises by 2025, addressing various issues raised by these companies [3] Group 4: Collaborative Innovation and Market Expansion - Hai'an promotes a "chain collaboration + industry-academia-research application" model to encourage enterprises to pursue specialized and innovative development [4] - The government has facilitated connections between local SMEs and leading domestic automotive companies, resulting in significant collaboration agreements, including a 200 million yuan order with Ideal Auto [5] - The city is committed to fostering the growth of unicorn enterprises and enhancing the quality of development for SMEs through collaborative efforts [5]

1月6日收盘后，亚辉龙披露《关于自愿披露签署战略合作框架协议的公告》称，公司与脑机星链签订《战略合作框架协议》，双方将在产品研发、市场 推广以及股权投资等方面开展合作。 亚辉龙公告称，脑机星链是一家以人工智能为核心驱动力，深耕非侵入式与侵入式双技术路径的企业，已开发脑电采集分析仪等产品。 1月7日，亚辉龙及有关责任人、英集芯及有关责任人，均被上交所予以监管警示。 | 证券代码 | 证券简称 | 监管类型 | 处理事由 | 涉及对象 | 处理日期 | | --- | --- | --- | --- | --- | --- | | 688575 | 亚辉龙 | 监管警示 | 关于深圳市亚辉龙生物科技股份有 | 上市公司,董秘 | 2026-01-07 | | | | | 限公司的决定书 | | | | 688209 | 英集芯 | 监管警示 | 关于深圳英集芯科技股份有限公司 | 上市公司,董秘 | 2026-01-07 | | | | | 的决定书 | | | 综合来看，亚辉龙、英集芯近期在发布的公告或互动平台上，提及与"脑机接口"等热点概念相关信息，但存在信息披露不准确、不完整，风险提示不充 分等问题。 监管 ...

Core Viewpoint - The Shanghai Stock Exchange issued a regulatory warning to Shenzhen Yahui Long Biotechnology Co., Ltd. for inaccurate and incomplete information disclosure regarding its strategic cooperation with Shenzhen Brain Machine Starlink Technology Co., Ltd. [1][2] Group 1: Company Actions - Shenzhen Yahui Long announced a strategic cooperation framework agreement with Brain Machine Starlink, focusing on product development, market promotion, and equity investment [1] - Following media attention, the company issued a supplementary announcement clarifying that Brain Machine Starlink's current research products only involve non-invasive technology and that some products are still in early development or preclinical stages [1][2] Group 2: Market Reaction - The announcement led to a 6.52% increase in the company's stock price, with trading volume rising by 299% compared to the previous trading day [2] Group 3: Regulatory Findings - The company was found to have inconsistent statements regarding the inclusion of invasive technology in its partnership, failing to adequately disclose risks related to cooperation feasibility and uncertainties [2] - The actions of the company violated multiple provisions of the Shanghai Stock Exchange's rules, leading to a regulatory warning for the company and its former board secretary, Wang Mingyang [2]

Core Viewpoint - Jindalai (688057) is making strategic investments in JiCi Medical and Zhongke Hongtai to enhance its presence in the fields of autologous cell technology and vascular interventional surgical robots, respectively [1] Group 1: Stock Performance - As of January 7, 2026, Jindalai's stock closed at 12.45 yuan, down 0.16% from the previous trading day, with a total market capitalization of 3.436 billion yuan [1] - The stock opened at 12.54 yuan, reached a high of 12.58 yuan, and a low of 12.42 yuan, with a trading volume of 15.0675 million yuan and a turnover rate of 0.44% [1] Group 2: Investment Announcements - Jindalai plans to invest 280 million yuan in JiCi Medical, acquiring a 34.00% stake; JiCi Medical focuses on the research and development of autologous cell technology and holds multiple invention patents, led by Professor Hu Min [1] - The investment in Zhongke Hongtai aims to establish a foothold in the vascular interventional surgical robot sector, with related products currently undergoing special review procedures for national innovative medical devices [1] - The announcement also details the purpose of the investments, valuation basis, synergistic effects, and risk management measures [1]

Market Overview - After a rapid rise, the global stock market is losing momentum, with signs of "overheating" [2][21] - The Dow futures are up 0.04%, while S&P 500 futures are down 0.08% and Nasdaq futures are down 0.24% [3][21] - The ADP report indicates a rebound in December employment, with private sector adding 41,000 jobs, below the market expectation of 47,000 [22] Geopolitical Factors - President Trump's threats regarding the potential acquisition of Greenland have heightened market tensions [22] - The U.S. military's actions leading to the capture of Venezuelan leader Maduro have drawn global market attention [22][24] - Greenland and Denmark have reiterated that the territory is not up for grabs, emphasizing local sovereignty [22] Economic Indicators - The upcoming U.S. labor market and business activity data are expected to test the sustainability of current market optimism [24] - The Bloomberg Dollar Index has continued its previous day's gains, with the dollar index slightly rising to 98.63 [26] - The market anticipates two more interest rate cuts from the Federal Reserve this year, which may weigh on the dollar [26] Commodity Market - Precious metals have weakened, with silver dropping below $80 and gold ending a three-day rise [23] - Oil prices have declined, with Brent crude down 0.8% to just above $60 [27] Corporate Highlights - Gold and silver stocks have seen pre-market declines, with notable drops including Kinross Gold down 1.71% and Harmony Gold down 3.18% [28] - Mobileye shares surged over 10% following the announcement of a $900 million acquisition of robotics company Mentee [30] - Ventyx Biosciences stock soared 70% as Eli Lilly plans to acquire the company for over $1 billion [32]

Group 1 - The core point of the article revolves around the revelation of Masaya Kawana, the daughter of Masayoshi Son, joining the biotech unicorn Spiber, raising questions about her potential role as a successor in the SoftBank empire [1][12][16] - Masaya Kawana, previously known for her work at Goldman Sachs, has a strong academic background and has been active in the business sector, indicating her capability to lead in the tech industry [5][7][9] - Spiber, the company she joined, is valued at $1.2 billion and focuses on sustainable technology, aligning with Son's vision for future investments [11][12] Group 2 - The article highlights a broader trend in the investment world where second-generation heirs are stepping into leadership roles as their predecessors retire, indicating a shift in power dynamics within major financial empires [2][3] - Masayoshi Son, at 68, has expressed intentions to continue leading SoftBank for another decade, emphasizing the importance of finding a suitable successor amidst a transitional phase for the company [12][16] - The narrative also includes examples of other wealthy heirs, such as Alexander Soros and Abigail Johnson, who have successfully taken over their family businesses, showcasing the evolving landscape of wealth management and investment leadership [17][24][25]

2025年，第一财经团队来到奉贤区海归小镇，关注这片热土正在发生的变化、发展的激情，奉贤区海归小镇深度调查研究观察之旅开启。这是我们关注中 小企业的再一次延续。我们交流的每一位走进海归小镇的创业者、海归小镇的初创设计者、海归小镇的运营者，都从容自信，饱含热情，为新一代海外归 来的学子们筑屋建巢，设计方案，全心为他们服务，期待他们能在这里安居乐业。我们不禁感叹：这是一个美好的时代，这个时代塑造并培育了追求美好 生活的我们。 回望1872年的上海，中国第一批外派留美幼童从这个城市出发，开始了他们计划长达15年的留学生活。那时的中国，以至于后来100多年间的中国，多少 留学生肩负着建设祖国的使命，他们做到了。如今，我们这一代人出发远行，再次归来，在实现家国梦的同时，我们个人理想的成分也更加凸显。正如上 海欧美同学会留美分会副会长兼秘书长、哥伦比亚大学校友会会长陆生对我们说的那样，"当年选择去美国留学，是因为我喜欢纽约这个城市；后来选择 回到上海，是因为我更爱中国"。 我们走访调研奉贤海归小镇，结合访谈奉贤海归小镇策划、建设、服务以及签约入驻企业等相关方，对海归小镇的建设和运营情况进行观察，从人才和企 业发展的微观故 ...

Core Viewpoint - The biotechnology sector in Hong Kong is experiencing growth potential due to policy support and strong demand, with innovative pharmaceutical companies leading the way in research and development [1] Group 1: Market Performance - On January 7, the Shanghai and Shenzhen markets showed mixed performance with slight fluctuations, while the communication, electronics, and comprehensive sectors led in gains [1] - The Hang Seng Biotechnology ETF (159615.SZ) rose by 2.82%, and Kangfang Biotech increased by 6.56% [1] Group 2: Industry Insights - Huatai Securities highlights that the biotechnology sector benefits from policy backing and has a robust pipeline of innovative drugs and high internationalization [1] - Global investment in biotechnology research and development continues to rise, indicating significant growth potential in sub-sectors like innovative drugs and medical devices [1] Group 3: Valuation and Economic Context - Current valuations of Hong Kong biotechnology companies are considered attractive, with expectations for industry prosperity to increase under supportive policies [1] - The technology sector in Hong Kong has faced valuation pressures due to factors like U.S. Federal Reserve interest rate hikes, but with stabilizing U.S. ten-year Treasury yields, there is an increasing expectation for liquidity improvement and valuation recovery [1] - The positive trend in China's economic recovery and ongoing policy support in the technology sector provide a solid fundamental basis for the Hong Kong technology sector [1] Group 4: Investment Value - The Hang Seng Biotechnology ETF (159615.SZ) serves as a key investment tool for the Hong Kong biotechnology sector, closely tracking the sector and covering areas such as innovative drugs and medical devices, thus presenting good investment value [1]

Group 1 - The core viewpoint of the news is the optimistic outlook for the Chinese stock market in 2026, with a recommendation from Goldman Sachs to overweight Chinese stocks, particularly A-shares and Hong Kong stocks [1][2] - The A500 index, representing core assets in China, has shown a strong performance with a 0.38% increase, driven by significant gains in stocks such as Wei股份 (up 12.26%) and 南大光电 (up 11.26%) [1] - The number of new A-share accounts opened in 2025 reached 27.44 million, a 9.75% increase from 2024, indicating growing investor interest [1] Group 2 - The A500 index is noted for its balanced representation of both traditional and emerging industries, with a focus on valuation, profitability, and dividends, suggesting an increasing demand for capital allocation towards it [1] - The top ten weighted stocks in the A500 index as of December 31, 2025, include 宁德时代, 贵州茅台, and 中国平安, collectively accounting for 20.33% of the index [2] - The market is expected to continue its upward trend, supported by key sectors such as commercial aerospace, artificial intelligence, and robotics, alongside cyclical sectors like oil and non-ferrous metals [2]